louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01816802: Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment
Official title: MERGE: MulticEnter ReGistry With Eeva
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: In vitro fertilization
Assisted reproductive therapy
Time-lapse image recording
Image analysis software
Lead sponsor: Progyny, Inc.
Sponsor class: INDUSTRY
First posted: 2013-03-22
Enrollment: 1200
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing in vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.

Brief summary: The purpose of this study is to record and evaluate the use of traditional morphology grading combined with Eeva in the treatment of in vitro fertilization.

Detailed description: This is a prospective, observational, single-arm, nonrandomized, multicenter study. Data will be collected to establish eligibility, at baseline, during the stimulation and in vitro fertilization process, during embryo culture, at embryo transfer, at 12-18 days post egg retrieval to verify biochemical pregnancy, and then typically at 5-6 weeks gestational weeks to verify clinical pregnancy.

Eligibility criteria: Inclusion Criteria:

* women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs.

Exclusion Criteria:

* history of cancer.
* gestational carrier.

Primary outcomes:
measure: Clinical Pregnancy Rate
timeFrame: 5-6 gestational weeks
Secondary outcomes:
Other outcomes:
measure: Multiple Pregnancy Rate
timeFrame: 5-6 gestational weeks
measure: Spontaneous Miscarriage Rate
timeFrame: 5-6 gestational weeks
Locations:
city: Encino
country: United States
facility: HRC Fertility
state: California
city: Palo Alto
country: United States
facility: Stanford Fertility and Reproductive Medicine Center
state: California
city: Redondo Beach
country: United States
facility: Reproductive Partners
state: California
city: San Francisco
country: United States
facility: Pacific Fertility Center
state: California
city: Farmington
country: United States
facility: Center for Advanced Reproductive Services (UCHC)
state: Connecticut
city: Chicago
country: United States
facility: Fertility Centers of Illinois - River North
state: Illinois
city: Chicago
country: United States
facility: Northwestern Medical Faculty Foundation
state: Illinois
city: Highland Park
country: United States
facility: Fertility Centers of Illinois, Highland Park IVF Center
state: Illinois
city: Melville
country: United States
facility: Long Island IVF
state: New York
city: Beachwood
country: United States
facility: University Hospital Fertility Center
state: Ohio
city: Cincinnati
country: United States
facility: Institute for Reproductive Health
state: Ohio
city: San Antonio
country: United States
facility: Fertility Center of San Antonio
state: Texas
Study officials:
affiliation: Progyny, Inc.
name: Shehua Shen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02555202: Validation of French Version of LCADL and Dyspnea-12
Official title: Validation of the French Version of the London Chest Activity of Daily Living Scale (LCADL) and the Dyspnea-12 Questionnaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Copd
Keywords: dyspnea
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2015-09-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: copd patients stage 3 and 4

Brief summary: The main objective of this study is to develop and to validate a French version of the London Chest Activity of Daily Living (LCADL) and the Dyspnea 12 and to determine the reliability of this version for the evaluation of the dyspnea in the Activity of Daily Living in COPD patients (stages severe and very severe).


Eligibility criteria: Inclusion Criteria:

* COPD with FEV1\< 50% of predictive value

Exclusion Criteria:

* FEV1\> 50% of predictive value
* Patients with an exacerbation of COPD in the previous 30 days the inclusion

Primary outcomes:
measure: the Saint-Georges questionnaire, item Activity
timeFrame: 15 days
measure: MMRC Dyspnea scale
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Morlaix
country: France
facility: Brest University hospital
Study officials:
affiliation: CHU BREST, Département de médecine interne et pneumologie EA 3878, CIC INSERM 1412, IFR 148
name: Francis Couturaud, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00382902: Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses
Official title: Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to Two Marketed Multi-Purpose Solutions for Care of Silicone Hydrogel Soft Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contact Lens Care
Keywords: Contact Lens Care
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-10-02
Enrollment: 233
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study was to clinically evaluate the safety and effectiveness of a new multi-purpose disinfecting solution in patients wearing silicone hydrogel soft contact lenses.


Eligibility criteria: * Successful daily wear of Night \& Day® or Acuvue® Advance™ silicone hydrogel contact for at least two weeks.
* Use of AOSEPT® ClearCare™ only as the pre-study care regimen for at least two weeks (rewetting drops use is also acceptable).
* Successful lens wear for at least 8 hours per day.
* Vision correctable to 20/30.
* Normal eyes - no current ocular abnormalities that prevent successful contact lens wear.
* No corneal surgery within the past 12 months.
* No systemic disease that affects that eye or that could be worsened by the use of contact lenses or solutions.
* No over-the-counter or prescription ocular medication.
* No enrollment in another clinical study within 30 days prior to enrollment.

Primary outcomes:
measure: Corneal Fluorescein Staining (Type and Area)
measure: Conjunctival Staining
measure: Lens Deposits
measure: Subject Questions/Subject Likert Questionnaire
measure: Ocular Comfort and Symptom Scales
measure: Lens Replacement Incidence and Causality
measure: Corrected Visual Acuity with Study Lenses (Snellen)
measure: Average Lens Wearing Time
measure: Average Uncomfortable Lens Wearing Time
measure: Safety:
measure: Slit-lamp Findings - Cornea: Edema, Neovascularization, Infiltrates; Injection, Tarsal Abnormalities and Other Complications
measure: Adverse Events
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Portland Site
state: Maine
Study officials:
affiliation: Alcon Research
name: Leslie Napier
role: STUDY_DIRECTOR
References:
Clinical trial NCT00106002: Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Official title: A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Breast Neoplasms, Male
Carcinoma, Ductal
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2005-03-21
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the drug, to determine how much pemetrexed should be given to patients, and to collect DNA for future research regarding metastatic breast cancer. The collection of DNA is optional to the patient.


Eligibility criteria: Inclusion Criteria:

* Must have been diagnosed with either advanced or metastatic breast cancer.
* Chemotherapy has not been given for advanced or metastatic breast cancer.
* The diagnosis of advanced or metastatic breast cancer was made at least 12 months after chemotherapy was given after breast surgery.
* Able to carry out work of a light nature (for example, light housework, office work).
* Must be at least 18 years old.

Exclusion Criteria:

* Have received prior bone marrow or peripheral stem cell transplantation.
* Have received prior chemotherapy for metastatic breast cancer.
* Are currently pregnant or breast-feeding.
* Have an active infection that your doctor decides will affect your safety.
* Are unable to take folic acid or vitamin B12.

Primary outcomes:
measure: Overall Tumor Response
timeFrame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression
Secondary outcomes:
measure: Toxicity Profile: Adverse Events (Common Terminology Criteria for Adverse Events, Grade 3 and 4, Present in >5% of Participants)
timeFrame: every 14 day cycle, and during 30-days post-therapy follow-up and long-term follow-up
measure: Duration of Tumor Response
timeFrame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression
measure: Progression-Free Survival Time
timeFrame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression
measure: Overall Survival Time
timeFrame: every 14 day cycle, during 30-days post-therapy follow-up, and every 6 months during the long-term follow-up
Other outcomes:
Locations:
city: Dallas
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
state: Texas
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00395902: Post Transplant Study
Official title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Tansplant
Secondary Hyperparathyroidism
Hyperparathyroidism
Keywords: Sensipar
cinacalcet
Mimpara
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2006-11-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Time perspective: RETROSPECTIVE

Brief summary: Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients


Eligibility criteria: Inclusion Criteria:

* Adults \>= 18 years old
* Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

* Subjects who received Sensipar before undergoing a kidney transplant
* Subjects receiving dialysis post-transplant

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01015521: Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
Official title: A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Breast Neoplasm
Keywords: breast cancer
Lead sponsor: Tigris Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2009-11-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.


Eligibility criteria: Inclusion Criteria:

* ER+ or TN Breast Cancer
* Progression on an aromatase inhibitor if ER+
* Prior treatment with taxane if TN
* 18 years or older
* Adequate organ function
* Measurable lesion

Exclusion Criteria:

* symptomatic pulmonary disease
* brain metastases
* pregnant females

Primary outcomes:
measure: Clinical Benefit Response
timeFrame: 6 months
Secondary outcomes:
measure: Progression Free Survival
timeFrame: 6 monhts
Other outcomes:
Locations:
Study officials:
References:
citation: Saito R, Miki Y, Hata S, Ishida T, Suzuki T, Ohuchi N, Sasano H. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Res Treat. 2017 Feb;161(3):399-407. doi: 10.1007/s10549-016-4063-x. Epub 2016 Nov 30.
Clinical trial NCT03047421: Influence of Different Methods of Measurement in the Accuracy of DES-OSA and P-SAP Scores
Official title: Influence of Different Methods of Measurement in the Accuracy of DES-OSA and P-SAP Scores
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea, Obstructive
Lead sponsor: Astes
Sponsor class: OTHER
First posted: 2017-02-09
Enrollment: 1682
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients scheduled for an anesthetic preoperative consultation

Brief summary: DES-OSA and P-SAP scores have been validated to detect OSA (Obstructive Sleep Apnea).

One item of P-SAP and DES-OSA is the measurement of neck circumference. The aim of this study is to compare the influence of different methods of neck circumference measurement in the accuracy of DES-OSA and P-SAP scores to detect OSA.


Eligibility criteria: Inclusion Criteria:

* All patients scheduled for an anesthetic preoperative consultation

Exclusion Criteria:

* \< 18 years

Primary outcomes:
measure: Accuracy of DES-OSA
timeFrame: one month
measure: Accuracy of P-SAP
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Bouge
country: Belgium
facility: Clinique Saint-Luc of Bouge
state: Namur
Study officials:
affiliation: Astes
name: Eric DEFLANDRE, MD, FCCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05289921: To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Official title: Multi Center, Phase III Clinical Trial to Evaluate the Safety and Efficacy of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Post Stroke Upper Limb Spasticity
Lead sponsor: Huons Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-03-22
Enrollment: 198
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigational Product: LIZTOX inj 100unit(HU-014) Title : Multi Center, Phase III Clinical Trial to Evaluate the efficacy and Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity Sites and investigators : Asan Medical Center(Seoul), Min-ho Chun, M.D, Ph.D Objective : To evaluate the efficacy and safety of LIZTOX inj in the treatment of Post Stroke Upper Limb Spasticity


Eligibility criteria: Inclusion Criteria:

* A subject who is diagnosed with Stroke at least six weeks prior to Screening.
* A subject who has Modified ashworth scale(MAS) score which Wrist Flexor is ≥ 2 and Flexor or Finger Flexor is ≥ 1.
* A subject with a Disability assessment scale(DAS)of at least ≥ 2 in one of the categories of hand hygiene, clothing, upper extremity, or pain for evaluation.

Exclusion Criteria:

* A subject who has medical history following. (Allergy, Chemodenervation(within 6 months), Tendon lengthening(within 6 months), Intrathecal baclofen.Aspiration pneumonia, etc.)
* A subject who has history of any diseases following. (neuromuscular junction disorder, NMJ, myasthemia gravis, MG, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis, ALS, Skin disease, Dysphagia, etc.)
* From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis implantation within 6 Weeks
* Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.
* A subject who tend to bleed or are taking anti-coagulant drugs.
* A sugject who is undergoing rehabilitation(physical therapy, occupational therapy, exercise therapy) or Splinting in the area where medication for clinical trials is scheduled to be administered.
* A sugject who has muscle atrophy, fixed joint/muscle contracture in the area where medication for clinical trials is scheduled to be administered.
* Any condition that, in the view of the investigator, would interfere with study participation.

Primary outcomes:
measure: MAS score improvement at Wrist Flexor
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT02402621: Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP
Official title: Comparison Between Conventional and Model-based Infusion Strategy of Intravenous Patient-controlled Analgesia in Patients Undergoing Robot Assisted Laparoscopic Radical Prostatectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2015-03-30
Enrollment: 111
Sex: MALE
Minimum age (years): 20
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparing postoperative analgesics requirements and complications between conventional and model-based infusion strategy of intravenous patient-controlled analgesia in patients who undergoing robot assisted laparoscopic radical prostatectomy

Group A: conventional intravenous patient-controlled analgesia, Group B: model-based infusion strategy of intravenous patient-controlled analgesia

Detailed description: The investigators compared postoperative analgesics requirements and complications between conventional and model-based infusion strategy of intravenous patient-controlled analgesia (IV PCA) in patients who undergoing robot assisted laparoscopic radical prostatectomy (RALP)

Group A: conventional IV PCA, Group B: model based IV PCA

1. Primary endpoint: comparison of postoperative analgesic requirements in patient undergoing robot assisted laparoscopic radical prostatectomy (RALP) between conventional patient controlled analgesia (PCA) (Group A) and effective-compartment based dosing strategy of PCA (Group B)
2. Secondary endpoint: 1) VAS analysis between two groups, 2) postoperative nausea and vomiting analysis between two groups, 3) complication evaluation between two groups

Eligibility criteria: Inclusion Criteria:

* Patient who is scheduled to get a robot assisted laparoscopic radical prostatectomy
* Patient who agree to get a patient controlled analgesia

Exclusion Criteria:

* American Society of Anesthesiologist (ASA) physical status over III
* History of alcohol or drug addiction
* History of acute or chronic pain or pain treatment
* Allergic to opioid analgesics
* BMI over 30 kg/m2
* History of sleep apnea or respiratory complications

Primary outcomes:
measure: Amount and number of postoperative analgesic requirements
timeFrame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Secondary outcomes:
measure: Number of participants with complications
timeFrame: Up to 48 hours
measure: Visual Analog Scale (VAS)
timeFrame: Up to 48 hours
measure: Postoperative nausea and vomiting
timeFrame: Up to 48 hours
measure: Respiratory rate, oxygen saturation
timeFrame: Up to 48 hours
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Young-Kug Kim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02019121: Dexmedetomidine and Renal Transplants
Official title: Dexmedetomidine and Renal Transplants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Failure
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2013-12-24
Enrollment: 797
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Renal transplant patients

Brief summary: Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function. Investigators hope to elucidate any association between renal transplant patients and perioperative dexmedetomidine administration, these include (but are not limited to) UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate. Investigators will research both living and cadaveric renal transplants.


Eligibility criteria: Inclusion Criteria: Patients greater than or equal to 18 years old that underwent renal transplant at UC Davis Medical Center -

Exclusion Criteria: Patients that did not undergo renal transplants and patients less than 18 years old will be excluded from the study.

-

Primary outcomes:
measure: Cr/GFR improvement, postoperative mortality/morbidity (within 30 days) and overall complications
timeFrame: 5 years
Secondary outcomes:
measure: Graft failure, length of hospital stay (LOS), length of ICU stay, re-admission rate, infections, pulmonary complications.
timeFrame: 5 years
Other outcomes:
measure: length of intubation time, and length of ventilation time
timeFrame: 5 years
Locations:
city: Sacramento
country: United States
facility: UC Davis Health System
state: California
Study officials:
affiliation: University of California, Davis
name: Hong Liu, M.D.
role: PRINCIPAL_INVESTIGATOR
References: